5-4-2004

Experimental and Theoretical Studies on the Pharmacodynamics of Cisplatin in Jurkat Cells

Kirk A. Tacka  
*Syracuse University*

Dava Szalda  
*Syracuse University*

Abdul-Kader Souid  
*State University of New York*

Jerry Goodisman  
*Syracuse University, goodisma@syr.edu*

James C. Dabrowiak  
*Syracuse University, jcdabrow@syr.edu*

Follow this and additional works at: http://surface.syr.edu/che

Part of the *Chemistry Commons*

Recommended Citation


This Article is brought to you for free and open access by the College of Arts and Sciences at SURFACE. It has been accepted for inclusion in Chemistry Faculty Scholarship by an authorized administrator of SURFACE. For more information, please contact surface@syr.edu.
Experimental and Theoretical Studies on the Pharmacodynamics of Cisplatin in Jurkat Cells

Kirk A. Tacka,† Dava Szalda,‡ Abdul-Kader Soud,§ Jerry Goodisman,† and James C. Dabrowiak*‡

Departments of Chemistry and Bioengineering and Neuroscience, Syracuse University,
111 College Place, CST Rm1-014, Syracuse, New York 13244-4100, and Department of Pediatrics,
Upstate Medical University, State University of New York, 750 East Adams Street,
Syracuse, New York 13210

Received May 4, 2004

For Jurkat cells in culture exposed to cisplatin (1), we measured the number of platinum adducts on DNA and showed that it is proportional to the AUC, the area under the curve, for cisplatin. The number of platinum-DNA adducts is measured immediately following exposure to drug. The AUC is calculated either as the product of the initial cisplatin concentration and the exposure time or as the integral under the concentration vs time curve for the unreacted dichloro species, which decreases exponentially. We also show that the number of adducts correlates with decreases in respiration, with the amount of DNA fragmentation, and with cell viability, all measured 24 h after exposure to the drug. To study the reactions of cisplatin at concentrations approaching clinical relevance (65 μM), we use two-dimensional [1H15N]HSQC NMR and the 15N-labeled form of the drug, cis-Pt(15NH3)2Cl2, 1. In the absence of cells, 1 reacts with components of the growth medium and also transforms slowly (k0 = 0.205 h⁻¹ at 37 °C) into the chloro-aquo species, cis-[Pt(15NH3)2Cl(H2O)]⁺ (2), which at the pH of the medium (pH 7.15), is mainly in the deprotonated chloro-hydroxy form, cis-Pt(15NH3)2-Cl(OH) (4). The concentration of 2 (4), as measured by HSQC NMR, decreases due to reaction with components of the medium. In the presence of 5 million or more cells, the concentration of 1 decreases with time, but the NMR signal for 2 (4) is not seen because it is rapidly removed from solution by the cells, keeping its concentration very low. These experiments confirm that the species preferentially removed from the medium by cells is 2 (4) and not 1. Our findings are discussed in the context of a kinetic model for platination of nuclear DNA by cisplatin, which includes aquation of cisplatin outside the cell, passage of 2 through the cell membrane, reaction of reactive platinum species (RPS) in the cytosol with thiols, formation of adducts between RPS and accessible sites on genomic DNA, and removal of platinum from DNA by repair. Some of the rate constants involved are measured, but others can only be estimated. Calculations with this model show that little of the platinum reacts with intracellular thiols before reaching the nuclear DNA, indicating that binding to thiols is not important in cisplatin resistance. The model also predicts the circumstances under which the amount of platination of nuclear DNA is proportional to AUC.

Introduction

Cisplatin, cis-dichlorodiammineplatinum (II), is in wide clinical use for the treatment of a variety of cancers (1). A major problem with cisplatin therapy is the resistance associated with extended use of the drug (2). Because cisplatin-induced apoptosis is related to the amount of platinum (Pt) bound to genomic DNA, cellular mechanisms that reduce the number of Pt-DNA adducts are the main factors affecting cisplatin resistance. These include DNA repair (2, 3), efflux of Pt from cells (4−6), and reaction of the drug with glutathione (GSH) and metallothionein (MT) (2, 7−9). More recently, it has been shown that other biochemical processes, not directly related to platination of DNA, may also contribute to resistance. For example, thiolate adducts of cisplatin that form in the cytoplasm may affect the thiol/disulfide equilibrium thus blocking the cell from entering into apoptosis (10−12).

For cell cycle nonspecific drugs such as cisplatin, Ozawa et al. (13) showed that cytotoxicity is proportional to the product of the exposure time and extracellular drug concentration, referred to as the area under the curve or AUC. It is often the case that AUC is the important parameter in determining the antitumor activity of cisplatin and other drugs (14−17) although exceptions

* To whom correspondence should be addressed. Tel: 315-443-4601. Fax: 315-443-4070. E-mail: jcdabrow@syr.edu.
† Department of Chemistry, Syracuse University.
‡ Department of Bioengineering and Neuroscience, Syracuse University.
§ State University of New York.

‡ Department of Pediatrics, Upstate Medical University, State University of New York, 750 East Adams Street, Syracuse, New York 13210

Pharmacodynamics of Cisplatin in Jurkat Cells

1 at 37 °C) into the chloro-aquo species, cis-Pt(15NH3)2-Cl(OH) (4). The concentration of 2 (4), as measured by HSQC NMR, decreases due to reaction with components of the medium. In the presence of 5 million or more cells, the concentration of 1 decreases with time, but the NMR signal for 2 (4) is not seen because it is rapidly removed from solution by the cells, keeping its concentration very low. These experiments confirm that the species preferentially removed from the medium by cells is 2 (4) and not 1. Our findings are discussed in the context of a kinetic model for platination of nuclear DNA by cisplatin, which includes aquation of cisplatin outside the cell, passage of 2 through the cell membrane, reaction of reactive platinum species (RPS) in the cytosol with thiols, formation of adducts between RPS and accessible sites on genomic DNA, and removal of platinum from DNA by repair. Some of the rate constants involved are measured, but others can only be estimated. Calculations with this model show that little of the platinum reacts with intracellular thiols before reaching the nuclear DNA, indicating that binding to thiols is not important in cisplatin resistance. The model also predicts the circumstances under which the amount of platination of nuclear DNA is proportional to AUC.

Introduction

Cisplatin, cis-dichlorodiammineplatinum (II), is in wide clinical use for the treatment of a variety of cancers (1). A major problem with cisplatin therapy is the resistance associated with extended use of the drug (2). Because cisplatin-induced apoptosis is related to the amount of platinum (Pt) bound to genomic DNA, cellular mechanisms that reduce the number of Pt-DNA adducts are the main factors affecting cisplatin resistance. These include DNA repair (2, 3), efflux of Pt from cells (4−6), and reaction of the drug with glutathione (GSH) and metallothionein (MT) (2, 7−9). More recently, it has been shown that other biochemical processes, not directly related to platination of DNA, may also contribute to resistance. For example, thiolate adducts of cisplatin that form in the cytoplasm may affect the thiol/disulfide equilibrium thus blocking the cell from entering into apoptosis (10−12).

For cell cycle nonspecific drugs such as cisplatin, Ozawa et al. (13) showed that cytotoxicity is proportional to the product of the exposure time and extracellular drug concentration, referred to as the area under the curve or AUC. It is often the case that AUC is the important parameter in determining the antitumor activity of cisplatin and other drugs (14−17) although exceptions
are also well-known (18, 19). In addition to establishing the validity of AUC for cisplatin in different cell types, modeling the cytotoxicity of the drug using experimental rate data for binding/transfer events in the cell has also been attempted. Miyagi et al. (20) constructed a model to explain the cytoidal and DNA binding effects of nedaplatin, a cisplatin analogue. Their model included drug transport across the cell membrane and drug reaction with DNA and assumed cell death occurred when the percentage of DNA–Pt adducts exceeded a threshold. Assuming rate constants for the processes, the coupled differential equations were solved to obtain the percent of cells killed as a function of time and drug concentration in the extracellular fluid. In modeling cisplatin cytotoxicity, El-Kareh and Secomb (18) considered the uptake, efflux, DNA binding, and repair rates of the drug to produce a model that provided good fits to experimental data sets, including exposure times of ~100 h. Recently, we proposed a model for cisplatin binding to genomic DNA (21). Our model included transfer of cisplatin across the cell and nuclear membranes, platination of DNA, and reaction of cisplatin with cellular thiols and cellular drugs. The amount of Pt bound to DNA was calculated by solving coupled differential equations, assuming values for rate constants that gave agreement between calculated and measured results, since measured values for some of them were not available.

In an earlier study (22), we showed that alteration in mitochondrial function is a secondary effect of cisplatin cytotoxicity in Jurkat cells in culture. In this report, we simulate continuous injection of cisplatin by exposing Jurkat cells to different concentrations of the drug for different periods of time. We show that the AUC correlates with the amount of Pt bound to DNA immediately after drug exposure and with changes in cellular respiration, viability, and DNA fragmentation observed 24 h after exposure. Using two-dimensional (2D) $^{1}H$-localized HSQC NMR and the $^{15}N$-labeled form of the drug, cis-Pt($^{15}$NH$_3$)$_2$Cl$_2$ (1) (Figure 1), we identify the cisplatin species preferentially removed from the culture medium by the cells. Although not so far employed for cell studies involving cisplatin, HSQC NMR has been used to characterize solution chemistry and reaction products of cisplatin and some of its analogues (23–31). We find that in the cell culture medium at pH 7.15, cisplatin aquates to produce the chloro-aquo complex, cis-[Pt($^{15}$NH$_3$)$_2$(H$_2$O)Cl]$_2$ (2), which is in equilibrium with the chloro-hydroxy compound, cis-Pt($^{15}$NH$_3$)$_2$(OH)Cl (4) (Figure 1). The HSQC NMR studies show that compared to 1, the mono-aquated product, 2 (4), is more readily removed from the medium by the cells.

This and other information are used to improve our kinetic model of Pt binding to genomic DNA. The aquation of 1 to 2 is included (the rate constant is known) as well as the uptake of 2 and 4 by cells (with measured rate constants). In addition to helping to explain Pt binding to DNA and the AUC data, the model should provide a framework for understanding Pt cytotoxicity to cancer and normal cells. Suitably parametrized, it could then be used to suggest dosing protocols for Pt anticancer drugs, which maximize cancer cell kill while minimizing damage to normal cells.

**Materials and Methods**

**Chemicals.** All materials were reagent grade and used as supplied. Cisplatin (3.3 mM in 154 mM aqueous NaCl) was obtained from American Pharmaceutical Partners (Los Angeles, CA); the Pd(II) complex of meso-tetra(4-sulfonatophenyl)tetrabenzoporphyrin (Pd phosphor), sodium salt, was purchased from Porphyrin Products, Inc. (Logan, UT); proteinase k, ribonuclease A (DNase-free from bovine pancreas; contained ~80 units/mg), rotenone, adenosine 5′-diphosphate (ADP), bromophenol blue, xylene cyanol FF, and fatty acid free bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO); nonyl phenyl-poly(ethylene glycol) (Nonidet NP-40) was purchased from Fluka (Ronkonkoma, NY); agarose (molecular biology grade) was purchased from Promega (Madison, WI); Dulbecco’s phosphate-buffered saline (PBS; w/o calcium or magnesium), fetal bovine serum (FBS), and RPMI-1640 medium with 1-glutamine (pH 7.15) were purchased from Mediatech (Herndon, VA); DNA HyperLadder I [200–10 000 base pair (bp)] was purchased from Bioline USA Inc. (Randolph, MA). cis-Pt($^{15}$NH$_3$)$_2$Cl$_2$ was synthesized from K$_2$PtCl$_4$ (Sigma-Aldrich) and $^{15}$NH$_4$CO$_2$CH$_3$ (Cambridge Isotope Laboratories, Inc., Andover, MA) using an earlier reported procedure (22). The $^{15}$N-labeled drug was recrystallized from boiling 0.1 M HCl. Solutions.

The Pd phosphor for the respiration studies was dissolved in distilled deionized water (dH$_2$O) (~2.5 mg/mL or ~2.0 mM) and stored in the refrigerator for less than 2 weeks. Rotenone (1.0 mM) was freshly dissolved in absolute ethanol. Phosphate-citrate buffer consisted of 200 mM Na$_2$HPO$_4$, with the pH adjusted to 7.8 with 0.1 M citric acid. Proteinase k (20 mg/mL) and ribonuclease A (10 mg/mL) solutions were made in dH$_2$O and stored at ~20°C. Nonidet NP-40 0.25% (v/v) solution was made in dH$_2$O and stored at room temperature (RT). Gel loading buffer contained (v/v) 0.25% bromophenol blue, 0.25% xylene cyanol FF, and 30% glycerol in dH$_2$O. Tris-borate–EDTA (TBE) buffer contained 40 mM Tris, boric acid, and 2 mM EDTA (pH 8.3).

The Pd phosphor solution for the respiration experiments contained 2 µM Pd phosphor, 2% (w/v) BSA, and 5 mM ADP in RPMI (containing ~6 mM Na$_2$HPO$_4$ and 10 mM glucose); the final pH was ~7.5. The solution was freshly made in a 30 mL quartz tube and continuously stirred for at least 90 min prior to use.

**Cells.** The human T-cell lymphoma cell line, Jurkat, was a gift from Dr. Edward Barker. The cells were maintained in suspension culture under a fully humidified atmosphere containing 5% CO$_2$ at 37 °C. The medium was RPMI-1640 supplemented with 10% (v/v) FBS, 100 µg/mL streptomycin, 100 IU/mL penicillin, and 2.0 mM L-glutamine. The number of cells and their viability were determined immediately prior to experimental measurements by light microscopy, using a hemacytometer under standard trypan blue staining conditions (35).

Incubation of Cells with Cisplatin. Incubations were carried out in RPMI medium plus 10% FBS at 37 °C. Cells in logarithmic growth (~10^7/condition) were exposed to cisplatin using times and drug concentrations indicated in Table 1. At the end of the incubation periods, the cells were collected by centrifugation, washed, and analyzed immediately for Pt–DNA adducts or maintained in culture (drug-free medium) and analyzed 24 h later, for respiration, viability, and DNA fragmentation as described in the Materials and Methods. The numbers are the means ± SD of 2–3 experiments.

Pt–DNA Adducts. Cellular (genomic) DNA was extracted from Jurkat cells immediately following the incubations with cisplatin. Pt–DNA adducts per 10^6 nucleotides (nt) (Table 1) were determined by atomic absorption spectroscopy (AAS) as previously described (21).

Cellular Oxygen Consumption. Respiration was measured at RT in sealed vials containing cells suspended in 0.7 mL of the Pd phosphor solution 24 h after exposure to cisplatin. The substrate for the cells was glucose. The concentration of oxygen [O2] in the solution was measured as a function of time using the phosphorescence probe, Pd phosphor (34, 35). This method was based on oxygen quenching of phosphorescence of the Pd phosphor.

The rate of cellular mitochondrial oxygen consumption (μM O2 min⁻¹) was calculated as the negative slope of the linear portion ([O2] ≥ 150 μM) of the [O2] vs time curves. The value of k, a zero-order rate constant, was set equal to the negative slope of each curve divided by the total number of cells (in millions) in each sample. Each experiment included a measurement in the presence of rotenone (which inhibits complex I of the respiratory chain). The rate of oxygen consumption for the Pd phosphor solution without cells was (mean ± SD) 0.28 ± 0.05 μM O2 min⁻¹ and, for ~10^7 cells incubated with rotenone (50 μM at 37 °C for 1 h), 0.36 ± 0.16 μM O2 min⁻¹.

Extraction of DNA Fragments. DNA fragments were extracted as described (36) with some modifications. Cells were washed with PBS and suspended in 1.0 mL of ice-cold PBS. Cells (~3 × 10^9/condition) were fixed in 8.0 mL of ice-cold 70% ethanol. The suspension was incubated at −20 °C for 24 h and then centrifuged (1000 g for 5 min at 4 °C). The supernatant was discarded, and the ethanol was allowed to completely evaporate at RT. The pellet was suspended in 50 μL of phosphate-citrate buffer and incubated at 20 °C for 90 min. The suspension was centrifuged (as above), and the supernatant was transferred to a fresh tube. The supernatant was recentrifuged as above, and the supernatant was lyophilized in a Speed Vac. The lyophilized pellet was suspended in 6 μL of Nonidet NP-40 (0.5% solution), 6 μL of SDS (10%), 6 μL of ribonuclease A (10 mg/mL solution), and 2 μL of ribonuclease T1. After overnight incubation at 37 °C, 6 μL of proteinase k (20 mg/mL solution) was added and the mixture was incubated overnight. Twenty-four microliters of the gel-loading buffer was added (final volume ~50 μL).

Agarose Gel Electrophoresis. Approximately 22 μL of the above extract was loaded on 4 mm thick, 1.0% agarose gels, and electrophoresed at 25 V and 11 mA for ~15 h in TBE buffer. Each extract was loaded on two separated gels. The gels were stained in 300 mL of 0.5 μg/mL ethidium bromide for 30 min in the dark at RT. After destaining for 15 min in deionized water, the gels were stored at 4 °C in 300 mL of TBE. The images were captured using a Gel Doc digital camera system with Quantity One software (Bio-Rad, Richmond, CA).

Quantitation of Stained Gels. The digital image of the stained gel was captured after adjusting the exposure time and iris diaphragm of the camera so that the maximum pixel intensity was below saturation (22). The digital image was analyzed using Sigma Scan software (version 2.0, SPSS Inc.). Individual lanes were scanned from the loading well to the low molecular weight end of the streaks. Net intensity vs position plots were exported to Peak-Fit software (version 4.1, SPSS Inc.), and the total intensity in the range of 0.1–10.0 kilo base pair (kb) (in arbitrary units) for each lane was determined.

HSQC NMR. The 2D [1H15N]HSQC NMR spectra were recorded at 37 °C using Bruker ADVANCE 500 and 600 spectrometers equipped with triple axes probes. The frequencies were used as follows: [1H, 500.13 and 600.13 MHz; [15N, 50.646 and 60.81 MHz. The spectra, optimized for J(15N–1H) = 72 Hz, were recorded using a pulse sequence available in the Bruker software package. The NMR experiment was 2D, [1H–15N, with inverse detection, phase sensitive with ECHO/Antiecho-TPP1 gradient selection, with decoupling during acquisition. Samples were not spun during the experiment. Twenty NMR experiments (each 62 min in length, ns = 48) were conducted for each kinetic run with 1. For each NMR experiment, there were 1K data points in the proton dimension and 64 τ1 values. The sweep widths in the proton and nitrogen dimensions were 4006.41 (8.01 ppm) and 4054.06 (80 ppm), respectively. Processing included squared cosines apodization in both dimensions, and zero-filling along the remote dimension to create a symmetric matrix (1K × 1K). For some experiments, 15 to ~115 ppm on the 15N axis was searched. Peak volumes [the 15N satellites of cis-Pt(15N)Cl2 were not included] were calculated using Bruker software, and the volumes analyzed in the manner described in the text.
The kinetics of reaction of cisplatin in the absence of cells was measured using a solution containing 65 \( \mu M \) cis-\([\text{Pt}(\text{NH}_3)_2\text{Cl}_2] \) (Figure 1). The assignment of peaks that appear when 1 reacts in culture medium in the absence of cells was done by reference to the literature (31) and by collecting NMR data on solutions of cisplatin that were “aged” by allowing 4.2 mM 1 to stand for 24 h in 10 mM NaCl. This produces a mixture of 1 and its aquated forms 2 and 3 (31). A portion of the aged solution was added to the culture medium to give a concentration of 65 \( \mu M \) Pt, and NMR data for 1 h were obtained. The spectrum exhibited the same peaks as those observed when 1 hydrolyzes in culture medium, but the relative intensities of the peaks for 1 and 2 (4) were different, with more of the mono-aquo present in the aged samples. Peak assignments for the mono-aquated complex were further confirmed by determining the 2D HSQC NMR spectrum of an aged solution (described above) of cisplatin in 23 mM NaHCO\(_3\) buffer (pH 7.15). Acidification of this solution with 1 N HNO\(_3\) to values of pH in the range of 7.15 to 7 produced NMR spectra consistent with the earlier published assignments for 2 and 4 (31). This also confirmed that at pH 7.15, the peaks for 1 and 4b overlap.

The kinetics of reaction of cisplatin in the culture medium with \( \sim 1.5 \times 10^6 \) cells was measured using a solution containing 65 \( \mu M \) 1. The stock solution of drug in 154 mM aqueous NaCl was added to the cells in the medium, the suspension was mixed by pipet action, and the resulting mixture was added to the NMR tube.

On separate samples under NMR conditions in sealed tubes, cell viability was checked every hour for the first 8 h of the kinetic run and again at the end of the run, \( \sim 21 \) h. The viabilities of drug-treated and untreated cells were virtually the same, 91.8 \( \pm 0.5 \) vs 94.7 \( \pm 2.3 \)% respectively, during the first 8 h. At the end of the \( \sim 21 \) h exposure period, the viabilities were low but there was a measurable difference between untreated (27.5 \( \pm 7.8 \)% and treated cells (10.0 \( \pm 7.1 \)%). Moreover, at the end of the \( \sim 21 \) h exposure period, untreated cells resired twice as fast and had \( \sim 50\% \) fewer DNA fragments than cells treated with cisplatin under NMR-like conditions (data not shown).

**Results**

**Effect of AUC on Pt–DNA Adduct Formation by Cisplatin.** Pt–DNA adducts were measured at the end of the incubation periods indicated in Table 1. The amount of Pt–DNA adducts is plotted vs AUC, calculated as the product of the cisplatin concentration ([cisplatin]) (\( \mu M \)) and the exposure time (h), in Figure 2 (upper panel). DNA platination increased linearly with AUC (dashed line, \( R^2 > 0.94 \)). Jurkat cells treated with an AUC = 15 \( \mu M \) h (5 \( \mu M \) for 3 h, 10 \( \mu M \) for 1.5 h, or 15 \( \mu M \) for 1 h) produced \( \sim 5.9 \)–9.0 Pt adducts per 10\(^6\) nts. For AUC = 45 \( \mu M \) h (15 \( \mu M \) for 3 h, 30 \( \mu M \) for 1.5 h, or 45 \( \mu M \) for 1 h), the amount of Pt–DNA adducts was 3–4 times higher, and for AUC = 75 \( \mu M \) h, DNA platination increased by a factor of 4–5.

The calculation of AUC as concentration \( \times \) time, \( T \), is appropriate when the [cisplatin] is maintained constant, as in administering the drug by infusion into plasma. However, the NMR results (see below) show that in our experiments, the concentration of 1 decreased exponentially, [cisplatin] = (65 \( \mu M \)) \( e^{-kt} \), because of formation of the mono-aquated product 2 (4) and uptake of the latter by the cells, with a hydrolysis rate constant \( k_h \) of 0.205 h\(^{-1}\). Thus, the AUC can also be calculated as \( \int C \, dt = (C_0/k_h)(1 - e^{-kt}) \) where \( C_0 \) is the initial concentration of 1. A plot of the amount of Pt–DNA adducts vs AUC calculated in this way (“true AUC”) is shown in the lower panel of Figure 2, with the best linear fit. Although \( R^2 \) is slightly decreased (to 0.91), the fit is well within experimental error.

During the incubation periods with cisplatin, Pt–DNA adducts are continuously formed and removed (1, 2). Inhibition of the nucleotide excision repair mechanism has been shown to increase adduct levels \( \sim 2\)-fold (37). Thus, the Pt–DNA adducts that we measured were a net value representing the difference between the number of adducts formed and the number of adducts removed by repair.

**Effects of AUC on Cisplatin-Induced Impairment of Cellular Respiration, DNA Fragmentation, and Loss of Cell Viability.** The dependence of cellular mitochondrial oxygen consumption (measured 24 h after drug exposure) on AUC is shown in Table 1. A representative [O\(_2\)] vs time curve for each AUC value is shown in Figure 3. The rate of respiration decreases linearly with AUC (0–67.8 \( \mu M \) h, \( R > 0.95 \)). The effects of the AUC on cisplatin-induced DNA fragmentation measured 24 h after exposure to the drug are summarized in Table 1 and shown in Figure 4. The amount of fragmented DNA increases almost linearly (\( R > 0.94 \)) as a function of AUC. The percentage of viable cells (mean \( \pm \) SD) 24 h after exposure to drug is also given in Table 1. The percentage of viable cells decreases linearly with R > 0.96 (plots not shown).

**HSQC NMR.** These experiments showed that the amount of Pt bound to DNA, as well as other cytotoxicity parameters described above, were proportional to AUC.
Figure 3. Dependence of AUC on cisplatin-induced mitochondrial dysfunction as measured by decreased cellular oxygen consumption. An oxygen consumption curve for each AUC value (0, diamonds; 13.6 μM h, squares; 38.7 μM h, triangles; and 56.0 μM h, circles) from a representative experiment is shown. Cells (∼10^7 per condition) were incubated at 37 °C for the times and cisplatin concentrations indicated in Table 1 and then maintained in drug-free medium for 24 h at 37 °C. At the end of the incubation period, a small volume of each suspension was removed to determine cell count and viability. The remaining cells were washed with PBS, suspended in the Pd phosphor solution, and placed in the instrument. The values of k were calculated as described in the Materials and Methods. The average (mean ± SD) values of k for each AUC value from three independent experiments are shown in Table 1.

Figure 4. AUC dependence of cisplatin cytotoxicity as measured by DNA fragmentation. A representative gel is shown. The experimental conditions were as described in the legend to Table 1. Three experiments were done with results (mean ± SD) shown in Table 1. Lane 2 (from left): cells incubated with no addition for 3 h (AUC = 0). Lanes 3–5 are cells incubated with AUC = 11.2–13.6 μM h (lane 3, 5 μM, 3 h; lane 4, 10 μM, 1.5 h; and lane 5, 15 μM, 1 h). Lanes 6–8 correspond to AUC = 33.6–40.7 μM h (lane 6, 15 μM, 3 h; lane 7, 30 μM, 1.5 h; and lane 8, 45 μM, 1 h). Lanes 9–11 correspond to AUC = 56.0–67.8 μM h (lane 9, 25 μM, 3 h; lane 10, 50 μM, 1.5 h; and lane 11, 75 μM, 1 h). Lane 1 is a DNA HyperLadder I (200–10 000 bp).

The cisplatin species that formed in the culture medium were next identified using HSQC NMR. The addition of 65 μM cis-Pt[(15)NH₃]₂Cl₂ (1) to the cell culture medium without cells at 37 °C resulted in the slow disappearance of the peak for 1 at ¹H/(¹⁵)N, δ = 4.09/−68.0, and the appearance of a new peak at ¹H/(¹⁵)N, δ = 3.61/−80.5 (Figure 5). On the basis of earlier published assignments (31) and NMR data collected on “aged” solutions of 1 in this work, the latter peak was assigned to (¹⁵)NH₃ trans to the O of cis-Pt[(¹⁵)NH₃]₂(OH)Cl (4) (Figure 1). The peak for (¹⁵)NH₃ trans to Cl of 4 was at almost the same position as the peak for the two labeled ammonia molecules of 1 (29, 31). This gives rise to the asymmetric peak at ¹H/(¹⁵)N, δ = 4.09/−68.0 (Figure 5). Because the pKₐ for the deprotonation of 2 to form 4 is 6.41 (31), at pH 7.15, the distribution of species is ∼15% 2 and ∼85% 4.

In the culture medium without cells, the intensity of the cisplatin peak decreased exponentially with time (see Figure 6). The intensity of the peak assigned to the deprotonated aquated product 4 also decreased exponentially but more slowly. No peaks other than those for 1 and 4 were observed in the spectra. When 5 million or more cells are present, the intensity of the peak for 1 decreased with time (Figure 7), but the peak for 4 was not observed. A new peak (¹H/(¹⁵)N, δ = 3.98/−62.0) of low intensity appeared after several hours.

To further confirm that the peak assignments shown in Figure 5 were correct, we measured the kinetics of decrease of 1 in the culture medium. The intensity (volume) of the peak at ¹H/(¹⁵)N, δ = 3.61/−80.5, was subtracted from the intensity of the peak at δ = 4.09/−68.0, and the result was divided by 2 (two equal resonances present for 1). Fitting the first nine points (t < 9 h) to an exponential gave 106.47 e⁻⁰.205t, so that the value of the rate constant is kₙ = 0.205 h⁻¹ = 5.7 × 10⁻⁵ s⁻¹ at 37 °C, somewhat higher than the reported rate constant for the hydrolysis of cisplatin at 25 °C, 5.18 × 10⁻⁵ s⁻¹ (29).

Finally, we calculated the initial rate of decrease of 1 by subtracting the intensity of the peak at ¹H/(¹⁵)N, δ = 3.61/−80.5, from that of the cisplatin peak at each time (t) and fitting the first six points to a line. Assuming the initial concentration of 1 was 65 μM, the three experiments shown in Figure 6 gave 5.6 ± 1.1, 7.9 ± 1.8, and
9.3 ± 2.5 μM/h for the initial rate of decrease (standard error of fit given). Averaging the three, we obtain 7.6 ± 1.5 μM/h (average ± variance). Analysis of the data shown in Figure 7 (15 million Jurkat cells present) in the same way gave initial rates of decrease of 4.2 ± 0.8, 4.5 ± 1.6, and 5.8 ± 0.6 μM/h. Averaging the three, we obtain 4.8 ± 0.7 μM/h (average ± variance). This is significantly lower than the rate in the absence of cells. However, if the data for all t values are fitted to exponentials, the exponential parameter is essentially the same in the presence and absence of cells.

The interpretation of these results is that 1 aquates to produce 4 and also reacts with some components of the culture medium. The species 4 also reacts with some components of the culture medium, but because 4 is being produced from 1, the apparent rate of decay of the intensities for 4 is much slower. The products of the reactions of 1 and 4 with the medium are not seen in the NMR, either because the product molecules are of very high molecular weight or because there are too many different products and the concentration of any one is too low to be detected in the experiment. In the presence of 15 million cells, the peak arising from 4 is not observed in the HSQC NMR. In other experiments, not shown here, we have observed this peak when fewer than 5 million cells are present. The peak's absence indicates that 4 is removed from solution by the cells more rapidly than 1.

The identity of a new signal at 3.98/−62.0, which appears after 8–10 h in the presence of cells, is unknown. However, we note that measured cell viability remains high for ∼12 h, but it decreases rapidly for 12–20 h, indicating that apoptosis is taking place at these times. This suggests that the signal at 3.98/−62.0 is associated with a species formed by the reaction of 1 with components released from the cells to the medium during apoptosis.

**Discussion**

In this work, we show that the amount of Pt bound to genomic DNA of Jurkat cells correlates linearly with the AUC, calculated as the product of the initial concentration of cisplatin in the medium and the exposure time to
the drug. The correlation is slightly less good if the AUC is calculated as \( f \cdot C \cdot dt \), where \( C \) is the actual [cisplatin]. The NMR experiments show that the drug (form 1) slowly hydrolyzes to produce the mono-aquated form 2, which at the pH of the medium, forms mainly the deprotonated complex, 4. When 5 million or more cells are present in the medium, the NMR studies indicate that hydrolysis of 1 is occurring but 4 is not observed. That this signal is not observed in the presence of cells could be due to electrostatic or covalent binding of the mono-aquo complex to the surface of the cell and/or to the reaction of this compound with a high molecular weight molecule in the cytoplasm.

Other workers have observed that aquated forms of cisplatin are preferentially taken up by cells. Jennerwein and Andrews (38) and later Howell and co-workers (39) exposed human ovarian, head, and neck carcinoma cells to mixtures containing the aquated forms of cisplatin and measured the amount of Pt bound to DNA. They found that as compared to cisplatin itself, aquated forms of the drug are more effective at platinating DNA. In a later study, Pereira-Maia and Garnier-Suillerot (40) showed that the diaquated products, 5 and 6, compounds not observed in our experiments, are taken up by small lung cancer cells at a rate \( \sim 40 \) times faster than cisplatin. Although 5 and 6 are not likely to form in media with high chloride concentrations, e.g., culture media or blood, the compound appears to be actively pumped into the cell by a transport mechanism. Recently, it has been shown that proteins responsible for the transport of copper into the cell may also be responsible for the active uptake of Pt (5, 41). Clearly, determining the mechanism by which 2 (4) is removed from solution by Jurkat cells will require additional study.

Although the rate of decrease of [1] over time is about the same in the presence and absence of cells, the initial rate of decrease of [1] is larger when no cells are present. The reason for this may be that 1 reacts with some components of the culture medium, as well as aquating to 4, and that some of the components of the medium are absorbed by the cells at early times. The species 4 also reacts with components of the culture medium, but because 4 is being formed from 1 at the same time, the apparent rate of decrease of [4] is much smaller than that of [1].

The most important observation is that 4 never appears when 5 million or more cells are present. This shows that 4 is removed from solution by the cells much faster than 1. The RPMI medium contains \( \sim 3 \) \( \mu \)M GSH and \( \sim 370 \) \( \mu \)M cysteine, both of which are good nucleophiles for Pt. The fact that these compounds do not react with Pt species to produce products having S trans to \( ^{15} \text{NH}_3 (\delta^{15} \text{N} \sim -40 \text{ ppm}) (28) \) is an indication that in the culture medium these thiols are in their less reactive disulfide forms.

### Theoretical Model

Having determined that platination is proportional to AUC for Jurkat cells in culture and having found that cells remove 2 (4) more efficiently than 1 from the extracellular solution, we refined our kinetic model (21) of cisplatin binding to cellular DNA. The model considers the important processes involved in bringing extracellular Pt to nuclear DNA, where it forms the lesions, which lead to apoptosis. The processes considered in the model are shown in Figure 8 and discussed below. It is recognized that each process may involve several chemical or biochemical reactions.

(i) The first process is the aquation of the dichloro species, 1, to 2, which becomes a mixture of 2 and 4. The rate of aquation is \( k_b \cdot E \), where \( E \) is the concentration of 1 and \( k_b = 0.205 \text{ h}^{-1} \), as measured in the present study and elsewhere (29). The reverse rate is \( k_b \cdot [\text{Cl}^-] \cdot [2] \), where \( k_b \) can be calculated from \( k_b \) and the measured equilibrium constant (29). (ii) As has been shown in this work, the mono-aquo compound 2 (4) is removed from the extracellular solution by Jurkat cells. Ghezzi et al. (42) have recently measured the amount of Pt taken up by human MCF-7 breast cancer cells exposed to cisplatin. They confirmed that the uptake rate is proportional to \( E \), even at high concentrations and times. Although they did not determine the form of the Pt entering the cells, it is reasonable to assume that it is the same as that removed from the solution by the cells. We use the value of the rate constant that they determined, \( k_b = 4.2 \times 10^{-13} \text{ mol M}^{-1} \text{ h}^{-1} \) per cell. Measurements in our laboratory with Jurkat cells exposed to cisplatin gave a similar value for this rate constant (Centerwall and Tacka, personal communication). The rate constant for Pt entering the cell interior (as compared to becoming covalently bound to the outside) is certainly smaller than \( 4.2 \times 10^{-13} \text{ mol M}^{-1} \text{ h}^{-1} \) per cell, but we know of no way to determine it. This value of \( k_b \) is multiplied by the number of cells and divided by the reaction volume (\( V_{\text{reaction}} = 20 \text{ mL} \)) to get the rate of decrease of extracellular Pt concentration or divided by a cell volume (\( V_{\text{cell}} = 1 \text{ pL} \)) to obtain the rate of increase of intracellular concentration. (iii) In the cytosol, where [\( \text{Cl}^- \)] is much lower than outside the cell, free 2 (4) may lose chloride to form 5 (6). For the model, we consider all species in the cytosol together as reactive platinum species (RPS), the concentration of which (\( P \)) is determined by \( k_b \) and the extracellular concentration of 2 (4). (iv) The RPS may react with thiols such as GSH or MT, which may prevent platination of nuclear DNA (2, 7–20, 43). The reaction is assumed second-order with rate \( k_b \cdot SP \) where \( S \) is the concentration of thiol groups in

![Figure 8. Model showing the important processes leading to the platination of genomic DNA by cisplatin. The definitions of the terms used in the model are as follows: E, extracellular concentration of cisplatin; 1, \( k_b \), rate constant for hydrolysis of 1 to the mono-aquo form; 2, A, sum of concentrations of 2 and 4; \( k_2 \), rate constant for the conversion of 2 to 4; \( k_3 \), rate constant for the reaction of 1, 2, and 4 with components in the medium; \( k_4 \), rate of uptake of 2 and 4 into the cell; P, cytosolic concentration of RPS; D, number of available sites on DNA for RPS; \( k_5 \), rate constant for the reaction of RPS with DNA; S, total concentration of cellular thiols; \( k_6 \), rate constant for the reaction of cellular thiols with RPS; \( k_7 \) = rate constant for repair.](image-url)
the cytosol, \( \sim 3 \) mM for GSH plus MT (43), and \( k_b = 0.013 \) M\(^{-1}\) s\(^{-1}\) for GSH and 0.65 M\(^{-1}\) s\(^{-1}\) for MT reacting with 1 (21, 44, 45). The rates of reaction of 1 and 4 with nucleophiles should be similar because the leaving groups are Cl\(^-\) and OH\(^-\), respectively (46), so we approximate the rate constant for reaction of 4 with cellular thiols as 0.65 M\(^{-1}\) s\(^{-1}\). (v) We assume that Pt crosses the nuclear membrane by passive diffusion (21, 47) and then reacts with nuclear DNA by a second-order reaction. The rate of formation of Pt–DNA adducts is given by \( k_2PD \), \( P \) being the intracellular RPS concentration and \( D \) being the number of available DNA sites to which the RPS can bind. The rate constant for the mono-aquo complex at pH 6.0 at 25 °C to form a monoadduct with guanine in an oligonucleotide duplex in vitro has been measured as 1.06 M\(^{-1}\) s\(^{-1}\) (25). However, this does not seem applicable to the cell because the rate measurements were made with both reactants uniformly distributed in solution, so that the process by which the RPS reaches the compartment containing the DNA (the nucleus) was not included. Rather than add another parameter to the model, we have chosen to consider transport of RPS to the interior of the nucleus and subsequent reaction with DNA sites as a single process, with rate \( -dD/dt = k_2DP \). (vii) The initial concentration of exposed DNA sites, \( D_0 \), may be estimated as follows. The prefered binding site is GG (1) and about 1/5 of the 5 \( \times \) 10\(^6\) bases in the nuclear DNA are Gs, so there are about 2 \( \times \) 10\(^6\) GG binding sites. Estimating that only about 1% of the bases are exposed to attack by RPS and that there are other binding sites, we estimate \( D_0 \) as 3 \( \times \) 10\(^6\). Because the number of Pt adducts is always much less than \( D_0 \), \( D \) remains approximately equal to \( D_0 \), which means only the value of \( k_2D_0 \), and not the value of \( D_0 \), is important. Using the estimated value of \( D_0 \), we choose the value of \( k_2 \) to give platination rates comparable to those measured in the AUC experiments described here. (viii) All species outside the cell react with the medium, with a first-order rate constant for reaction of \( \text{Pt}^2+ \) with cellular thiols as \( k_4 \). The concentration of exposed DNA sites, \( D_0 \), may be estimated from measurements on neuroblastoma cells and subsequent reaction with DNA sites by a second-order reaction. The rate constant for reaction of \( \text{Pt}^2+ \) with cellular thiols is \( k_4 = 24.1 \) M\(^{-1}\) h\(^{-1}\) (reverse to aquation), \( k_4 = 0.101 \) h\(^{-1}\) (reaction with medium), \( k_4 = 0.65 \) M\(^{-1}\) h\(^{-1}\) (reaction of Pt with thiols), \( k_4 = 50 \) M\(^{-1}\) h\(^{-1}\) per site (reaction of Pt with DNA), and \( k_3 = 0.4 \) h\(^{-1}\) (repair). The number of available sites is \( D_0 = 3 \times 10^6 \). Upper panel: curves show the concentrations of extracellular cisplatin, 1, chloro-aquo species 2, and hydroxy species 4, and intracellular Pt. Lower panel: calculated number of Pt–DNA adducts as a function of time. The slope (rate of formation of adducts) is constant for \( t > \sim 0.5 \) h.

![Figure 9](image)

Figure 9. Results of calculations using the model of Figure 8. The initial concentration of cisplatin, \( [1] = 65 \) \( \mu \)M. The rate of transport of aquated cisplatin into a cell is \( k_2A \) per cell where \( A \) is the concentration (M) of aquated cisplatin outside the cell and \( k_2 = 4.2 \times 10^{12} \) mol h\(^{-1}\) M\(^{-1}\). Other rate constants are as follows: \( k_4 = 0.205 \) h\(^{-1}\) (auration), \( k_3 = 24.1 \) M\(^{-1}\) h\(^{-1}\) (reverse to aquation), \( k_4 = 0.01 \) h\(^{-1}\) (reaction with medium), \( k_4 = 0.65 \) M\(^{-1}\) h\(^{-1}\) (reaction of Pt with thiols), \( k_4 = 50 \) M\(^{-1}\) h\(^{-1}\) per site (reaction of Pt with DNA), and \( k_3 = 0.4 \) h\(^{-1}\) (repair). The number of available sites is \( D_0 = 3 \times 10^6 \).

Because form 1 interconverts with form 2 only (not form 4). Also

\[
\frac{dA}{dt} = k_1E - k_mE - k_1[\text{Cl}^-]A \frac{[H^+]}{K_a + [H^+]} - k_eA \frac{N_{\text{cells}}}{V_{\text{reaction}}} \tag{2}
\]

\[
\frac{dP}{dt} = k_2A \frac{1}{V_{\text{cell}}} - k_0PS - k_4PD \tag{3}
\]

\[
\frac{dD}{dt} = -k_d'PD + k_e(D_0 - D) \tag{4}
\]

\[
\frac{dS}{dt} = -k_s'PS \tag{5}
\]

Note that \( dP/dt \) is in \( \mu \)mol, whereas \( dD/dt \) is in millions of sites/h. The ratio of \( k_d' \) to \( k_d \) is thus the cell volume (\( V_{\text{cell}} = 10^{-12} \) L) multiplied by Avogadro’s number and divided by \( 10^8 \), i.e., \( 6 \times 10^5 \). Equations 1–5 are solved numerically using the Runge–Kutta method with variable step size.

Figure 9 shows results obtained for an initial concentration of 1 of 25 \( \mu \)M, assuming 10 million cells present, as in the AUC measurements. The upper panel shows the concentrations of 1 and 2 + 4 outside the cell, as well
as the total concentration of Pt inside the cell, vs time. The concentration of Pt inside the cell becomes larger than that outside the cell. The concentration of 2 + 4 is always too small to be seen in the NMR measurements, even though these species are formed from 1, because aquated cisplatin passes into the cell as rapidly as it is formed. At \( t = 3 \) h, corresponding to AUC = 75 \( \mu M \) h, the number of Pt−DNA adducts is 1.45 \( \times 10^5 \), corresponding to 48.4 adducts per million nt (lower panel of Figure 9). This is calculated based on the total number of nts in the genome, not only those exposed to platination, to correspond with what is actually determined in the AUC experiments. The value of \( k_b \), \( 7 \times 10^9 \) h\(^{-1}\) M\(^{-1}\) per site, was chosen so that this agrees (see Table 1) with what is found experimentally.

The thiol concentration (not shown in Figure 9) decreases by less than 0.01%, even at 4 h. The extent of Pt−thiol reaction is small because the rate of the value of the rate constant \( k_b \), and the RPS concentration are small. The total number of Pt−DNA adducts is comparable to the number of Pt−thiol adducts and much less than the number of Pt atoms in the cytosol. In fact, only about 3% of the Pt in the cell has reacted with nuclear DNA at 3 h. This is about what is stated in the literature, that ~1% of the cellular Pt is bound to DNA (42). The total amount of Pt in the cell is mainly determined by the rate at which 2 or 4 enters the cell.

Calculations with our model show that with 5 million cells and an original total [cisplatin] of 65 \( \mu M \), A never exceeds 15 \( \mu M \). Because the sensitivity of the NMR experiment (see Figures 6 and 7) prevents measurement of concentrations below ~15 \( \mu M \), this explains why the mono-aquo species is never detected in experiments with 15 million cells. Model calculations with \( E_0 = 65 \) \( \mu M \) show that with fewer than 5 million cells, A would exceed 15 \( \mu M \) and would be detectable. Experiments (not reported here) confirm this.

A series of calculations using this model with various values of \( E_0 \) and \( t \) show that the amount of platination is proportional to AUC except for very short times. As seen in Figure 9 (lower panel), the number of adducts grows at a constant rate for \( t > 0.5 \) h. For \( t < 0.5 \) h, concentrations of the chloro-aquo species inside and outside the cell vary rapidly and the rate is not constant. The constancy of the rate of adduct formation implies that the amount of platination is proportional to AUC.

**Summary and Conclusions**

In this report, we show that for Jurkat cells in culture exposed to cisplatin, the number of Pt adducts on DNA is proportional to AUC. Here, AUC is the area under the concentration vs time curve for unreacted (dichloro) cisplatin. The number of Pt−DNA adducts is measured immediately following exposure to drug. We also show that the number of DNA adducts correlates linearly with a decrease in respiration, measured 24 h after removal of drug; there is no effect on respiration immediately after drug exposure. The number of adducts also correlates linearly with the amount of DNA fragmentation, measured 24 h after drug exposure, and with cell viability.

We also report on the use of HSQC NMR to study the reactions of cisplatin, at concentrations approaching clinical relevance, in the presence and in the absence of cells. In the absence of cells (but with cell growth medium present), the dichloro form 1 is transformed into the mono-aquo species (\( k_b = 0.205 \) h\(^{-1}\) at 37 °C) because the chloride concentration, originally 154 mM in the cisplatin stock solution, is lowered to 104 mM in the culture medium. As seen in the HSQC NMR, the concentration of the mono-aquo species decreases because of this transformation and reaction with the components of the medium. In the presence of cells, the concentration of 1 also decreases (with a somewhat smaller initial rate than in the absence of cells), reflecting the transformation to the mono-aquo species. However, the signal for the latter is not seen because 2 (4) is removed from the medium by the cells as rapidly as it is formed, keeping its concentration too low to be measured in these experiments. From experiments of this type, it is possible to measure the rate at which the mono-aquo species is accumulated by cells.

We present a phenomenological model for platination of nuclear DNA by exposure to cisplatin. The processes included are aquation of cisplatin outside the cell, passage of the chloro-aquo species through the cell membrane, reaction of RPS in the cytosol with thiols, formation of adducts between RPS and accessible DNA sites in the nucleus, and DNA repair. We have measured values for the repair rate and for the rate constant for the hydrolysis of cisplatin at 37 °C in culture medium. From the equilibrium constant for hydrolysis (29), we derive the rate constant for the reverse reaction. The rate constant for the reaction of 4 with thiols at pH 7.4, \( k_b \), was estimated to be the rate constant for the reaction of 1 with cellular thiols (43–45). The uptake rate for Pt, presumably in the form 2 or 4, by human breast cancer cells has been measured (42) and is used as an estimate of the rate at which Pt enters Jurkat cells. The rate constant \( k_d \) for the reaction of Pt with nuclear DNA (actually the rate of Pt transport to the nuclear DNA followed by its reaction with DNA) is not known. It turns out that only \( k_d D \) is important, where \( D \) is the number of available Pt binding sites. Estimating \( D \), we choose a value of \( k_d \) in the model to give a number of adducts comparable to what we found in the AUC experiments.

Despite the approximations and assumptions, the model helps us to understand our experimental results and indicates what processes are important. For example, the model shows under what circumstances the amount of platination of nuclear DNA is proportional to AUC. It also shows that most of the Pt in the cell remains unreacted. The fraction of intracellular Pt that reacts with intracellular thiols is quite small. This suggests that thiols contribute to cell protection (and cell resistance) in ways other than simply reacting with Pt before it reaches the nuclear DNA. However, it may be that too small a value was used for the rate constant \( k_b \) (our value was obtained from in vitro measurements). Rate constants for reaction of Pt drugs with some drug thiols are more than an order of magnitude larger (44, 48).

In addition, the model explains why the chloro-aquo species is not seen in our NMR experiments with 5 million or more cells present and predicts correctly the maximum number of cells, which can be used if this species is to be seen. The NMR experiments show that the species preferentially removed from the culture medium by Jurkat cells is mostly the mono-aquated form of the drug, which, at neutral pH, is mostly deprotonated. Because forms of cisplatin with one or two bound water molecules are more reactive to nucleophiles than 1, the
antitumor agents is dependent on concentration–time product.

Cancer Chemother. Pharmacol. 21, 185–190.


